Cephalon executives to join Arana board
This article was originally published in Scrip
Executive Summary
Four senior Cephalon executives have joined the board of Arana Therapeutics, following Cephalon's acquisition of a majority holding in the Australian antibody firm. They are chairman and CEO Dr Frank Baldino Jr, chief financial officer Kevin Buchi, chief scientific officer Dr Jeffry Vaught and chief medical officer Dr Lesley Russell. Dr Baldino has been appointed chairman to succeed Robin Beaumont, who will step down to become lead independent director. Gordon Black and Lincoln Chee have retired as non-independent directors from Arana's board.